journal article·2020-11Open access

Engineering tetravalent IgGs with enhanced agglutination potencies for trapping vigorously motile sperm in mucin matrix

Bhawana Shrestha, Alison Schaefer, Elizabeth C. Chavez, Alexander J. Kopp, Timothy M. Jacobs, Thomas R. Moench, Samuel K. Lai

Acta Biomaterialia· Volume 117

Abstract

Multivalent antibodies such as sIgA can crosslink motile entities such as sperm and bacteria, creating agglomerates that are too large to permeate the dense mucin matrix in mucus, a process commonly referred to as immune exclusion. Unfortunately, sIgA remains challenging to produce in large quantities, and easily aggregates, which prevented their use in clinical applications. To develop sIgA-like tetravalent antibodies that are stable and can be easily produced in large quantities, we designed two IgGs possessing 4 identical Fab domains, with the Fabs arranged either in serial or in the diametrically opposite orientation. As a proof-of-concept, we engineered these tetravalent IgG constructs to bind a ubiquitous sperm antigen using a Fab previously isolated from an immune infertile woman. Both constructs possess at least 4-fold greater agglutination potency and induced much more rapid sperm agglutination than the parent IgG, while exhibiting comparable production yields and identical thermostability as the parent IgG. These tetravalent IgGs offer promise for non-hormonal contraception and underscores the multimerization of IgG as a promising strategy to enhance antibody effector functions based on immune exclusion.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Reproductive System and Pregnancy · Complement system in diseases · Blood groups and transfusion

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. The immune geography of IgA induction and function10.1038/mi.2007.6 ↗
2. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut10.1038/mi.2011.41 ↗
3. IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections10.1038/mi.2013.120 ↗
4. Influenza-binding antibodies immobilise influenza viruses in fresh human airway mucus10.1183/13993003.01709-2016 ↗
5. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus10.1016/j.actbio.2016.07.019 ↗
6. The function of immunoglobulin A in immunity10.1002/path.1877 ↗
7. Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV10.4161/mabs.36336 ↗
8. Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles10.1007/s00018-015-2074-0 ↗
9. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: A randomized controlled trial10.1097/01.AOG.0000278078.45640.13 ↗
10. Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production10.4236/abb.2013.44A006 ↗
11. Evaluating the bottlenecks of recombinant IgM production in mammalian cells10.1007/s10616-014-9693-4 ↗
12. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma10.1158/1078-0432.CCR-06-2919 ↗
13. Development trends for human monoclonal antibody therapeutics10.1038/nrd3229 ↗
14. Fab-based bispecific antibody formats with robust biophysical properties and biological activity10.1080/19420862.2015.1022694 ↗
15. Engineering Polymer-Binding Bispecific Antibodies for Enhanced Pretargeted Delivery of Nanoparticles to Mucus-Covered Epithelium10.1002/anie.201814665 ↗
16. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model Jonathan10.1016/S2214-109X(18)30029-9 ↗
17. Disparities in Rates of Unintended Pregnancy In the United States, 1994 and 200110.1363/3809006 ↗
18. Declines in Unintended Pregnancy in the United States, 2008-201110.1056/NEJMsa1506575 ↗
19. Contraceptive use and behavior in the 21st century: A comprehensive study across five European countries
20. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks10.1177/2042098614548857 ↗
21. Complications and Contraindications of Oral Contraception10.1097/00003081-198109000-00016 ↗
22. Contraindications to combined oral contraceptives among over-the-counter compared with prescription users10.1097/AOG.0b013e31820b0244 ↗
23. Contraception and cardiovascular disease10.1093/eurheartj/ehv141 ↗
24. Current contraceptive use and variation by selected characteristics among women aged 15-44: United States, 2011-2013
25. The sperm-cervical mucus contact test: a preliminary report10.1016/S0015-0282(16)41726-7 ↗
26. Induction of the shaking phenomenon by IgA class antispermatozoal antibodies from serum10.1111/j.1600-0897.1985.tb00333.x ↗
27. Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits10.1095/biolreprod56.1.153 ↗
28. N-linked glycan of a sperm CD52 glycoform associated with human infertility10.1096/fasebj.13.11.1303 ↗
29. A male genital tract-specific carbohydrate epitope on human CD52: Implications for immunocontraception10.1034/j.1399-0039.2002.600502.x ↗
30. Monoclonal antibodies to human trophoblast and sperm antigens: Report of two WHO-sponsored workshops, June 30, 1986-Toronto, Canada10.1016/0165-0378(87)90089-1 ↗
31. Establishment and characterization of a human hybridoma secreting monoclonal antibody with high titers of sperm immobilizing and agglutinating activities against human seminal plasma10.1016/0165-0378(87)90051-9 ↗
32. Production of heavy-chain class-switch variants of human monoclonal antibody by recombinant DNA technology
33. Transient expression of human antibodies in mammalian cells10.1038/nprot.2017.126 ↗
34. The proteomics protocols handbook
35. Characterization of proteins by size-exclusion chromatography coupled to multi-angle light scattering (Sec-mals)
36. Light scattering in solutions10.1063/1.1707436 ↗
37. Accuracy in multiangle light scattering measurements for molar mass and radius estimations. Model calculations and experiments10.1021/ac030128+ ↗
38. nanoDSF: in vitro label-free method to monitor picornavirus uncoating and test compounds affecting particle stability10.3389/fmicb.2020.01442 ↗
39. Examination and processing of human semen
40. Relationships between sperm motility characteristics assessed by the computer-aided sperm analysis (CASA) and fertilization rates in vitro10.1023/A:1009420432234 ↗
41. Analysis of recombinant human semenogelin as an inhibitor of human sperm motility10.1095/biolreprod.109.081331 ↗
42. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract10.1016/j.jmb.2007.02.024 ↗
43. Convolutional neural networks automate detection for tracking of submicron-scale particles in 2D and 3D10.1073/pnas.1804420115 ↗
44. A broad range of Fab stabilities within a host of therapeutic IgGs10.1016/j.bbrc.2007.02.042 ↗
45. Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies10.1002/jps.21104 ↗
46. Sperm counts and fertility in men: A rocky road ahead. Science & Society Series on Sex and Science10.1038/embor.2012.50 ↗
47. Sperm transport from the external cervical Os to the fallopian tubes in women: a time and quantitation study10.1016/S0015-0282(16)39908-3 ↗
48. Complement is activated by IgG hexamers assembled at the cell surface10.1126/science.1248943 ↗
49. Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece.10.4049/jimmunol.162.6.3448 ↗
50. Multimerization is required for antigen binding activity of an engineered IgM/IgG chimeric antibody recognizing a skin-related antigen10.1038/s41598-017-08294-2 ↗
51. Male subfertility10.1136/bmj.327.7416.669 ↗
52. Benchmark pregnancy rates and the assessment of post-coital contraceptives: an update10.1016/j.contraception.2015.01.002 ↗
53. The vagina as a route for systemic drug delivery10.1016/j.jconrel.2004.11.034 ↗
54. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases10.3201/eid0501.990107 ↗
55. A vaginal fluid simulant10.1016/S0010-7824(99)00010-4 ↗
56. Immunology of the human genital tract10.1097/00001432-200302000-00008 ↗
57. Antibodies may provide prolonged microbicidal activity due to their long residence time in the vagina
58. Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model10.1128/AAC.02465-16 ↗